Evidence map›Paper›PMID 40747213›Full record

ArticleRSC chemical biology2025

Defining STING-sterol interactions with chemoproteomics.

Ian Ford, Miranda Villanueva, Min Sub Lee, Quan D Zhou, Constance Yuen, Robert Damoiseaux, Steven J Bensinger, Keriann M Backus

Abstract read
In one paragraph

Article in RSC chemical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Regulation of STING activation by phosphoinositide and cholesterol.bioRxiv : the preprint server for biology · 2025
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ian FordDepartment of Microbiology, Immunology, and Molecular Genetics, Biomedical Research Sciences Building, 615 Charles E. Young Drive, University of California Los Angeles CA 90095 USA SBensinger@mednet.ucla.edu.ORCID https://orcid.org/0000-0002-3236-5739
Miranda VillanuevaDepartment of Biological Chemistry, David Geffen School of Medicine, Biomedical Research Sciences Building, 615 Charles E. Young Drive, University of California Los Angeles CA 90095 USA kbackus@mednet.ucla.edu.ORCID https://orcid.org/0000-0002-4892-8356
Min Sub LeeDepartment of Microbiology, Immunology, and Molecular Genetics, Biomedical Research Sciences Building, 615 Charles E. Young Drive, University of California Los Angeles CA 90095 USA SBensinger@mednet.ucla.edu.
Quan D ZhouDepartment of Microbiology, Immunology, and Molecular Genetics, Biomedical Research Sciences Building, 615 Charles E. Young Drive, University of California Los Angeles CA 90095 USA SBensinger@mednet.ucla.edu.ORCID https://orcid.org/0000-0002-0184-4884
Constance YuenDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA Los Angeles CA 90095 USA.
Robert DamoiseauxDepartment of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA Los Angeles CA 90095 USA.ORCID https://orcid.org/0000-0002-7611-7534
Steven J BensingerDepartment of Microbiology, Immunology, and Molecular Genetics, Biomedical Research Sciences Building, 615 Charles E. Young Drive, University of California Los Angeles CA 90095 USA SBensinger@mednet.ucla.edu.
Keriann M BackusDepartment of Biological Chemistry, David Geffen School of Medicine, Biomedical Research Sciences Building, 615 Charles E. Young Drive, University of California Los Angeles CA 90095 USA kbackus@mednet.ucla.edu.ORCID https://orcid.org/0000-0001-8541-1404

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
UCLA NIGMS T32 Program AssessmentT32GM007185 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TORRES, JORGE · 1985 to 2020
$21.7M
Understanding the Influence of Lipid Homeostasis on T cell FunctionP01HL146358 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BENSINGER, STEVEN J · 2019 to 2023
$11.7M
Chemistry Biology Interface Training ProgramT32GM136614 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Patrick G. Harran · 2020 to 2026
$2.8M
A systems-level approach to decipher the protein interactome.DP2GM146246 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BACKUS, KERIANN MARIE · 2021 to 2024
$2.3M
NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NHLBI NIH HHS P01 HL146358NIGMS NIH HHS DP2 GM146246NIGMS NIH HHS T32 GM007185NIGMS NIH HHS T32 GM136614
6 · The paper itself

Abstract

Stimulator of interferon genes (STING) is an intracellular pattern recognition receptor that plays a key role in responding to cytosolic DNA and cyclic dinucleotides. STING activity is tightly regulated to avoid aberrant STING activity, excessive type I IFN responses, and resultant autoinflammatory disease. As such understanding the molecular events regulating STING activity is critical. Recent work has revealed cellular cholesterol metabolism also functions to modulate STING activity, although the molecular events linking cholesterol homeostasis with STING remain incompletely understood. Here we pair genetic and chemoproteomic approaches to inform the mechanisms governing cholesterol modulation of STING activity. Using gain- and loss-of-function systems, we find that markedly increasing SCAP-SREBP2 processing and resultant cholesterol synthesis has little impact on STING activity. In contrast, we find that genetic deletion of

Identifiers

PMID40747213
PMCPMC12308517

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.